Short answer
PUMA BIOTECHNOLOGY, INC. (PBYI) filed an 8-K current report with the SEC on June 16, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders re-elected all eight director nominees for one-year terms through the 2027 annual meeting.
PUMA BIOTECHNOLOGY, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders re-elected all eight director nominees for one-year terms through the 2027 annual meeting
- KPMG LLP ratified as independent auditor for fiscal 2026, with 42,612,940 votes supporting
- Executive compensation approved on an advisory basis, with 29,326,673 votes for and 7,878,580 against
- Stockholders rejected extending CEO Alan Auerbach’s warrant through October 4, 2028
- Rejected warrant covers 2,116,250 shares at a $16.00 exercise price, limiting its requested term extension beyond October 4, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PUMA BIOTECHNOLOGY, INC. 8-K filings
Get the next PBYI 8-K as it lands
Follow PBYI for push alerts, or ask the research agent what this filing means.